Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426785 | 0.93 | PSMB1 (0.56) | MEN1KMT2AHRH3KDM4E | |
| SCHEMBL5416531 | 0.91 | KDM4E (0.56) | MEN1KMT2AHRH3KDM4E | |
| SCHEMBL5420560 | 0.81 | MEN1 (0.49) | MEN1KMT2AHRH3KDM4E | |
| SCHEMBL5422932 | 0.78 | MEN1 (0.57) | MEN1KMT2AHRH3KDM4EKCNH2 | |
| SCHEMBL492315 | 0.76 | MEN1 (0.97) | MEN1KMT2AHRH3KCNH2ACHE | |
| SCHEMBL5857827 | 0.75 | MEN1 (0.94) | MEN1KMT2AHRH3KCNH2ACHE | |
| SCHEMBL19287693 | 0.74 | MEN1 (1.00) | MEN1KMT2AHRH3KCNH2ACHE | |
| SCHEMBL3581930 | 0.73 | HRH3 (0.89) | HRH3L3MBTL1KCNH2ACHERAD52 | |
| SCHEMBL15701629 | 0.72 | MEN1 (0.72) | MEN1KMT2AHRH3KDM4EL3MBTL1 | |
| SCHEMBL14970581 | 0.72 | MEN1 (0.88) | MEN1KMT2AHRH3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099891-A1 | Medicinal compositions and combinations | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-03 | — | — | US | disclosed |
| EP-1695706-A1 | MEDICINAL COMPOSITIONS AND COMBINATIONS | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-6420381-B1 | ACYL-COA: CHOLESTEROL ACYL TRANSFERASE (ACAT) INHIBITORY ACTIVITY, AND IS USEFUL AS AN AGENT FOR TREATMENT OF HYPERLIPIDEMIA AND ATHEROSCLEROSIS. | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1104763-A1 | NAPHTHYRIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099891-A1 | Medicinal compositions and combinations | HMGCR, APOB, CYP46A1 | MEN1 2994/4885KMT2A 441/4885HRH3 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.